Organization and board members
Hartwig Medical Foundation is an independent foundation partly funded by philanthropy. The foundation has no profit motive and reinvests all acquired funds in achieving its mission. Hartwig Medical Foundation is an independent foundation partly funded by philanthropy. The non-profit foundation reinvests all acquired funds in achieving its mission. Directors Hans van Snellenberg, Edwin Cuppen and Lotte Smits oversee day-to-day management.
- Constantijn van Oranje-Nassau (chair)
- Rob Defares, founder and Director of IMC
- Guido Derckx, partner at Loyens & Loeff
- Chris Polman, neurologist, represents the Dutch Federation of University Medical Center and chair of the board of Amsterdam UMC’s VUmc location and vicechair of the AMC location
- Emile Voest, internist-oncologist, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, director of Cancer Core Europe
The Scientific Board consists of renowned national and international scientists and advises the Board of Directors and Supervisory Board on scientific and strategic choices, when requested. In addition, the Scientific Board evaluates requests for data for scientific value and feasibility.
- René Bernards, biomedical geneticist, Head of Molecular Carcinogenesis at the Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam
- Han van Krieken, Rector of the board of Radboud University, Nijmegen
- Bob Löwenberg, hematologist Erasmus MC, Rotterdam
- Roel Verhaak, professor Neurosurgery, Yale School of Medicine, Connecticut (US)
Data Access Board
The Data Access Board consists of a panel of independent experts and reviews data requests for access on legal, social and ethical aspects.
Meet our enthusiastic team of lab analysts, bioinformaticians, IT specialists, clinicians and more!
We want to extract the maximum amount of information from the patient’s tumor. This DNA test is the The complete DNA test is the best available tool to extract the maximum amount of information from the patient’s tumor. We only need one tissue sample with sufficient tumor cells. We literally analyze the entire genome, including parts of the DNA that show mutations of which we don’t yet know the importance. This test is tumor-independent and future-proof. These are the two most important advantages of WGS.